Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of Multiple-Dose Adjuvanted RSVPreF3 (Arexvy®) Vaccination Among Immunocompromised Persons

NCT07050732 is registered in ClinicalTrials.gov with Johns Hopkins University as lead sponsor.

NCT NCT07050732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07050732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of Multiple-Dose Adjuvanted RSVPreF3 (Arexvy®) Vaccination Among Immunocompromised Persons
Lead sponsor
Johns Hopkins University
Phase
Phase 2
Overall status
Recruiting
Start date
December 4, 2025
Completion date
April 30, 2028
Enrollment
170 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus (rsv)